Skip to content
SHM Abstracts | Society of Hospital Medicine Logo
  • Home
  • Meetings Archive
  • Browse By Category
  • Browse By Keyword
  • Search
  • Home
  • Meetings Archive
  • Browse By Category
  • Browse By Keyword
  • Search
Search2020-05-20T12:01:36-05:00
Search
Search by Abstract Number, Title, Keyword, or Authors
Category
Sub-Category

(Optional)

Session Type
Meeting
Search Results for Venous Thromboembolism
Abstract Number: 143
LESS LUMENS = LESS RISK
Hospital Medicine 2017, May 1-4, 2017; Las Vegas, Nev.
Background: Multi-lumen (ML) peripherally inserted central catheters (PICCs) are associated with increased risk of central line associated blood stream infection (CLABSI), venous thromboembolism (VTE) and increased cost compared to single lumen (SL) PICCs. Current guidelines recommend minimizing the number of PICC lumens. However, there is a paucity of literature to guide the selection of SL [...]
Abstract Number: 144
ECONOMIC BENEFIT FOR ACUTE-CARE HOSPITALS THROUGH USING BETRIXABAN FOR EXTENDED-DURATION VTE PROPHYLAXIS OVER 35-42 DAYS
Hospital Medicine 2018; April 8-11; Orlando, Fla.
Background: Venous thromboembolism (VTE) in hospitalized medically ill patients is a leading preventable cause of morbidity and mortality in the United States. About half of VTE events occur following discontinuation of standard-duration in-hospital prophylaxis and hospital discharge. The APEX study evaluated Betrixaban for in-hospital to home VTE prophylaxis and is the first FDA approved anticoagulant [...]
Abstract Number: 145
EXTENDED-DURATION VTE PROPHYLAXIS WITH BETRIXABAN SAVES COST COMPARED TO STANDARD-DURATION ENOXAPARIN ACROSS INPATIENT AND OUTPATIENT SETTINGS
Hospital Medicine 2018; April 8-11; Orlando, Fla.
Background: Venous thromboembolism (VTE) in hospitalized medically ill patients is a leading preventable cause of morbidity and mortality in the United States. About half of VTE events occur following discontinuation of standard-duration in-hospital prophylaxis and hospital discharge. The APEX study evaluated Betrixaban for in-hospital to home VTE prophylaxis and is the first FDA approved anticoagulant [...]
Abstract Number: 154
CAN WE PREDICT RISK FACTORS OF VENOUS THROMBOEMBOLISM AMONG CANCER INPATIENTS
Hospital Medicine 2020, Virtual Competition
Background: Increased risk of venous thromboembolism (VTE) has been noted among cancer patients as compared to non-cancer. Cancer associated thrombosis caused three folds increased hospitalizations, increased inpatient/outpatient medical and prescription claims, and increased total health care costs per patient. Our objective was to study demographic, clinical and laboratory risk factors for venous thromboembolism (VTE) among [...]
Abstract Number: 173
ATTITUDES AND PRACTICES REGARDING IN-HOSPITAL THROMBOPHROPHYLAXIS RISK ASSESSMENT MODELS
SHM Converge 2023
Background: In-hospital venous thromboembolism (VTE) remains an important preventable cause of morbidity/mortality. Multiple risk assessment models (RAMs) for VTE in hospitalized medical patients have been developed, validated, and endorsed by several national societies. Despite evidence and guidelines supporting risk stratification for VTE prevention, data suggest that prophylactic measures are not appropriately utilized. In a nation-wide [...]
Abstract Number: 180
ARE COATED PERIPHERALLY INSERTED CENTRAL CATHETERS ASSOCIATED WITH A REDUCED RISK OF CATHETER-RELATED COMPLICATIONS? AN ANALYSIS OF 45,680 DEVICES
Hospital Medicine 2020, Virtual Competition
Background: Peripherally inserted central catheters (PICCs) are associated with an increased risk of central line-associated bloodstream infection (CLABSI) and venous thromboembolism (VTE). Catheters that are coated or impregnated with antimicrobial and/or antithrombotic agents have been developed to prevent these complications. However, their effectiveness in preventing CLABSI and VTE is unclear. Using data from a large [...]
Abstract Number: 181
DELAYS OF VTE PROPHYLAXIS ON ADMISSION
SHM Converge 2021
Background: Venous thromboembolism (VTE) is a significant cause of morbidity and mortality for hospitalized patients. There are approximately 900,000 new VTE events and 100,000 VTE-related deaths every year. In the United States, more deaths occur due to VTE than breast cancer, AIDS, and motor vehicle accidents combined. VTE are considered preventable events with appropriate prophylaxis; [...]
Abstract Number: 182
VTE RISK AT DISCHARGE
SHM Converge 2021
Background: Venous thromboembolism (VTE) poses a significant risk to patients in the hospital setting, and studies have shown that VTE prophylaxis should be incorporated into the management of high-risk patients during their hospital stay. However, many of these patients are still high-risk for VTE at the time of discharge and for up to three months [...]
Abstract Number: 188
Venous Thromboembolism After Hospitalization in Trauma Patients: Does Prophylaxis Matter?
Hospital Medicine 2016, March 6-9, San Diego, Calif.
Background: Venous thromboembolism (VTE), both pulmonary embolism (PE) and deep vein thrombosis (DVT), causes morbidity and mortality in hospitalized patients. The duration of VTE risk in trauma, particularly after discharge, is not well understood, especially in the context of shortened hospital stays. Although guidelines provide recommendations for extended VTE prophylaxis after major orthopedic surgery, such [...]
Abstract Number: 189
POTENTIAL APPLICATION OF CURRENT GUIDELINE-DIRECTED HOSPITAL ACQUIRED VENOUS THROMBOEMBOLISM PROPHYLAXIS ON HOSPITALIZED CHILDREN
Hospital Medicine 2020, Virtual Competition
Background: Pediatric venous thromboembolism (VTE), although less common than in adults, is increasingly recognized as a significant and preventable cause of morbidity and mortality. There are no universal pediatric VTE guidelines, although the American College of Chest Physicians (ACCP) limits prophylaxis recommendations to a limited set of risk factors. Multiple centers have published institutional guidelines [...]
‹ Previous 1 2 3 4 5 6 Next ›
  • This Week

  • This Month

  • All Time

  • This Week

  • FEEDBACK THAT WORKS: IMPROVED BILLING THROUGH AUTOMATED PEER COMPARISON

  • NALTREXONE – INDUCED KRATOM WITHDRAWAL: A CALL FOR AWARENESS

  • A CASE OF AMANTADINE INDUCED LIVEDO RETICULARIS IN A PATIENT WITH MULTIPLE SCLEROSIS

  • LOSARTAN-INDUCED ELECTROLYTE DEPLETION

  • Cannabis Withdrawal Induced Hypertensive Urgency

  • This Month

  • FEEDBACK THAT WORKS: IMPROVED BILLING THROUGH AUTOMATED PEER COMPARISON

  • NALTREXONE – INDUCED KRATOM WITHDRAWAL: A CALL FOR AWARENESS

  • A CASE OF AMANTADINE INDUCED LIVEDO RETICULARIS IN A PATIENT WITH MULTIPLE SCLEROSIS

  • LOSARTAN-INDUCED ELECTROLYTE DEPLETION

  • Cannabis Withdrawal Induced Hypertensive Urgency

  • All Time

  • FEEDBACK THAT WORKS: IMPROVED BILLING THROUGH AUTOMATED PEER COMPARISON

  • ADDERALL INDUCED ISCHEMIC COLITIS

  • A CASE OF SKIN NECROSIS CAUSED BY INTRAVENOUS XYLAZINE ABUSE

  • Bc Powder Causing Intracerebral Bleed: Pitfalls of Overlooking Dosage of Seemingly Innocuous Otc Formulations

  • RECOGNIZING S1Q3T3 FOR WHAT IT IS: A NONSPECIFIC PATTERN OF RIGHT HEART STRAIN

© Society of Hospital Medicine | All Rights Reserved | Privacy Policy
Page load link
Go to Top